Survival impact of time to initiation of chemoradiotherapy after resection of newly diagnosed glioblastoma

被引:76
|
作者
Sun, Matthew Z. [1 ]
Oh, Taemin [2 ]
Ivan, Michael E. [1 ]
Clark, Aaron J. [1 ]
Safaee, Michael [1 ]
Sayegh, Eli T. [2 ]
Kaur, Gurvinder [2 ]
Parsa, Andrew T. [2 ]
Bloch, Orin [2 ]
机构
[1] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA
[2] Northwestern Univ, Dept Neurol Surg, Feinberg Sch Med, Chicago, IL 60611 USA
关键词
glioblastoma; overall survival; progression-free survival; treatment delay; The Cancer Genome Atlas; oncology; ADJUVANT TEMOZOLOMIDE; WAITING-TIMES; RADIOTHERAPY; DELAY; CONCOMITANT; RADIATION; EORTC;
D O I
10.3171/2014.9.JNS14193
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
OBJECT There are few and conflicting reports on the effects of delayed initiation of chemoradiotherapy on the survival of patients with glioblastoma. The standard of care for newly diagnosed glioblastoma is concurrent radiotherapy and temozolomide chemotherapy after maximal safe resection; however, the optimal timing of such therapy is poorly defined. Given the lack of consensus in the literature, the authors performed a retrospective analysis of The Cancer Genome Atlas (TCGA) database to investigate the effect of time from surgery to initiation of therapy on survival in newly diagnosed glioblastoma. METHODS Patients with primary glioblastoma diagnosed since 2005 and treated according to the standard of care were identified from TCGA database. Kaplan-Meier and multivariate Cox regression analyses were used to compare overall survival (OS) and progression-free survival (PFS) between groups stratified by postoperative delay to initiation of radiation treatment. RESULTS There were 218 patients with newly diagnosed glioblastoma with known time to initiation of radiotherapy identified in the database. The median duration until therapy was 27 days. Delay to radiotherapy longer than the median was not associated with worse PFS (HR = 0.918, p = 0.680) or OS (HR = 1.135, p = 0.595) in multivariate analysis when controlling for age, sex, KPS score, and adjuvant chemotherapy. Patients in the highest and lowest quartiles for delay to therapy (<= 20 days vs >= 36 days) did not statistically differ in PFS (p = 0.667) or OS (p = 0.124). The small subset of patients with particularly long delays (>42 days) demonstrated worse OS (HR = 1.835, p = 0.019), but not PFS (p = 0.74). CONCLUSIONS Modest delay in initiation of postoperative chemotherapy and radiation does not appear to be associated with worse PFS or OS in patients with newly diagnosed glioblastoma, while significant delay longer than 6 weeks may be associated with worse OS.
引用
收藏
页码:1144 / 1150
页数:7
相关论文
共 50 条
  • [21] Impact of extent of resection of newly diagnosed glioblastomas on survival: a meta-analysis
    AbdelFatah, Mohamed A. R.
    Kotb, Ali
    Said, Mohamed Ahmed
    Abouelmaaty, Emad M. H.
    EGYPTIAN JOURNAL OF NEUROSURGERY, 2022, 37 (01)
  • [22] Impact of extent of resection of newly diagnosed glioblastomas on survival: a meta-analysis
    Mohamed A. R. AbdelFatah
    Ali Kotb
    Mohamed Ahmed Said
    Emad M. H. Abouelmaaty
    Egyptian Journal of Neurosurgery, 37
  • [23] Clinical Outcomes of Moderately Hypofractionated Concurrent Chemoradiotherapy for Newly Diagnosed Glioblastoma
    Kim, Nalee
    Lim, Do Hoon
    Choi, Jung Won
    Lee, Jung-Il
    Kong, Doo-Sik
    Nam, Do-Hyun
    Seol, Ho Jun
    YONSEI MEDICAL JOURNAL, 2023, 64 (02) : 94 - 103
  • [24] Impact of Surgical Resection on Survival Outcomes After Chemoradiotherapy in Anal Adenocarcinoma
    Li, Richard
    Shinde, Ashwin
    Fakih, Marwan
    Sentovich, Stephen
    Melstrom, Kurt
    Nelson, Rebecca
    Glaser, Scott
    Chen, Yi-Jen
    Goodman, Karyn
    Amini, Arya
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2019, 17 (10): : 1203 - 1210
  • [25] Everolimus shortens survival of newly diagnosed glioblastoma patients
    Eric T. Wong
    Kenneth D. Swanson
    Journal of Neuro-Oncology, 2018, 140 : 179 - 180
  • [26] Conditional Probability of Survival in Patients With Newly Diagnosed Glioblastoma
    Polley, Mei-Yin C.
    Lamborn, Kathleen R.
    Chang, Susan M.
    Butowski, Nicholas
    Clarke, Jennifer L.
    Prados, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (31) : 4175 - 4180
  • [27] Survival with dacarbazine and fotemustine in newly diagnosed glioblastoma multiforme
    B Fazeny-Dörner
    M Veitl
    C Wenzel
    K Rössler
    K Ungersböck
    K Dieckmann
    M Piribauer
    J Hainfellner
    C Marosi
    British Journal of Cancer, 2003, 88 : 496 - 501
  • [28] THE CONDITIONAL PROBABILITY OF SURVIVAL IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS
    Polley, Mei-Yin C.
    Lamborn, Kathleen R.
    Chang, Susan M.
    Butowski, Nicholas
    Clarke, Jennifer L.
    Prados, Michael
    NEURO-ONCOLOGY, 2010, 12 : 55 - 55
  • [29] Everolimus shortens survival of newly diagnosed glioblastoma patients
    Wong, Eric T.
    Swanson, Kenneth D.
    JOURNAL OF NEURO-ONCOLOGY, 2018, 140 (01) : 179 - 180
  • [30] Survival with dacarbazine and fotemustine in newly diagnosed glioblastoma multiforme
    Fazeny-Dörner, B
    Veitl, M
    Wenzel, C
    Rössler, K
    Ungersböck, K
    Dieckmann, K
    Piribauer, M
    Hainfellner, J
    Marosi, C
    BRITISH JOURNAL OF CANCER, 2003, 88 (04) : 496 - 501